BAY 1862864

Drug Profile

BAY 1862864

Alternative Names: BAY-1862864

Latest Information Update: 05 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action CD22 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Nov 2015 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Late-stage disease) in Sweden (IV) (NCT02581878)
  • 23 Oct 2015 Bayer plans a phase I trial for Non-Hodgkin's lymphoma (Second-line or greater, Late-stage disease) in United Kingdom and Sweden (NCT02582878)
  • 01 Oct 2015 Preclinical trials in Non-Hodgkin's lymphoma in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top